UBS analyst Peter Lennox-King believes this new source of cash for GE, as well as the benefits, is a boon for the company.
“The sale of GE BioPharma to Danaher effectively puts the leverage question to bed,” Lennox-King said.
Deutsche Bank analyst Nicole DeBlase was the odd one out among the group, however, despite raising the firm’s price target on GE to $11 a share.
“GE is left with the less attractive parts of the Healthcare business,” DeBlase said of the deal.
Here’s what major Wall Street analysts said about GE’s deal.